https://www.cosmopolitan.com/sex-love/a29136061/double-standard-about-sex-drive/

https://www.womenshealthmag.com/sex-and-love/a29196905/sexual-disorder-low-libido/

Brand new articles. Perfect and enormous target. Littered with Vyleesi ads. It's time, fellow longs!


Cosmopolitan is an international fashion and entertainment magazine for women.

The magazine is one of the best-selling magazines.

There are 64 worldwide editions of Cosmopolitan, and the magazine is published in 35 languages, with distribution in more than 100 countries making Cosmopolitan the largest-selling young women's magazine in the world.

Cosmopolitan has found popularity in its newfound medium, the "discover" section on Snapchat.

After only the first full month of Vyleesi launch, AMAG reported on November 1:

• 12.5 million women reached via online means (marketing)
• 120,000 prospective patients filled out symptom questionnaires (demand)
• 3000 prescriptions written (sales)
• 1300 physicians prescribing Vyleesi (increased scale)

Again…after only ONE full month. There are 3.5 more months not accounted for since that report.

Yet we hear constantly on these boards that Vyleesi has no sales, zero marketing, zero demand, no one knows about it, & Vy is a flop. Maybe it will be but I’m betting it won’t and that we’re simply in the dark for reasons we'll soon know. GL.

Full transcript where I got this info is here: https://www.fool.com/earnings/call-transcripts/2019/11/01/amag-pharmaceuticals-inc-amag-q3-2019-earnings-cal.aspx

• HSDD is common. In fact, approximately 1 in 10 premenopausal women in the US has it = Enormous Market. https://www.vyleesi.com/know-hsdd/

• The injector pen (not a shot/syringe) is painless. Watch this: https://bit.ly/31GF7Q4

• No one outside of AMAG/PTN knows the sales numbers yet, however, AMAG stated that Vyleesi sales are off to a strong start with virtually no marketing. We'll soon know what "strong start" means...Any other hypotheses as to sales are mere biased conjecture and should be ignored.

• A plethora of reviews and videos online describing efficacy…in both genders. Easy to find. Of course, no drug on the planet works for every patient.

• No debt & ~92M in the bank & ROW to sell

• https://www.ncbi.nlm.nih.gov/m/pubmed/27181790/?i=3&from=/31381550/related = a randomized, placebo-controlled dose-finding trial: CONCLUSION: In premenopausal women with female sexual dysfunctions, self-administered, as desired, subcutaneous BMT was safe, effective, and well tolerated

• At a MC ~50M over the cash on hand with an FDA approved sex drug sounds as good as it gets IMHO. GL.

Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
6:30 am | PR Newswire
Mentions RLMD

NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Relmada Therapeutics Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced today that the Relmada team will ring the NASDAQ stock market opening bell tomorrow, Friday, October 18, 2019, at 9:30 AM ET, to commemorate the Company's recent uplisting to the NASDAQ Capital Market.

"Opening NASDAQ is a tremendous honor and a wonderful opportunity to celebrate our recent uplisting to the NASDAQ Capital Market," said Sergio Traversa, CEO of Relmada. "This exciting event comes on the heels of our positive top-line results from the Phase 2 study of REL-1017 in individuals with treatment resistant depression, which we announced earlier this week. We look forward to continuing the development of this important program and focus on bringing a new effective treatment to the millions of patients suffering from depression."

For a livestream of the ceremonies, please visit NASDAQ's MarketSite Webcam: https://new.livestream.com/nasdaq/live.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. For more information, please visit Relmada's website at www.relmada.com.


SOURCE Relmada Therapeutics, Inc.

Related Links
http://www.relmada.com

That was before a very risky binary event which took place yesterday. They aced the trials, the binary event. Most of the risk was therefore removed (there's always some but a failed trial would have sent this well below 10 like you say - that's now behind us). The PIPE price is now 101% irrelevant. And a 250M MC is a joke in depression based biotech. 1B MC is a short term potential (within 6 months) based on the market size for TRD/MDD.

Can you explain the secondary offering you suggest? Dilutive or non-dilutive? Would it be the major shareholders unloading some of their shares or how does that work? Does that have a positive impact on us the shareholders?

Thanks in advance.

Results are in.

https://www.relmada.com/news-events/press-releases/detail/200/relmada-therapeutics-announces-top-line-results-from

Results are in.

https://www.relmada.com/news-events/press-releases/detail/200/relmada-therapeutics-announces-top-line-results-from

Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

NEW YORK, October 14, 2019 - Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will release top-line data from its Phase 2 study of REL-1017 in patients with treatment resistant depression tomorrow, October 15, 2019, before the market opens.

At 8:30 AM Eastern Time the Company will host a conference call to discuss the results of the study with the investment community.

Conference Call and Webcast Details

Time: 8:30 AM Eastern Time / 5:30 AM Pacific Time
Toll Free: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13695600
Webcast (with slides): http://public.viavid.com/index.php?id=136568

About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. For more information, please visit Relmada's website at www.relmada.com.

Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Just fyi. StockTwits now has an rlmd board which is getting some traction in case you want to also follow that one.

Good post. We're expecting top-line data shortly. Do you expect that to include the secondary endpoints in the same report or just the primary endpoints? Since secondary are post hoc, I'm not sure they're necessarily included in top-line results. Thank you for any further input.

Relmada uplisted to Nasdaq!

https://seekingalpha.com/news/3504438-relmada-uplisted-nasdaq?dr=1#email_link

Good stuff.

I can't find any reason for the 50% drop in AXSM (followed by a slight recovery).

Could it be that word is out of RLMD's imminent results?

Any thoughts on why they'd exercise the warrants pre-data? They're at a fixed cost so I'd imagine it'd be worthwhile to wait to make sure data is good and let the price escalate...unless there's an intent to sell these respective shares prior to data.

Hi Vic, how are you feeling about RLMD of late? Any change from your earlier perspectives?

I'd say $9M+ in the bank is a good thing and should ward off any need to dilute for a good year+ so that's great.

I thought we would have gotten the news by now about NASDAQ or the results. Hope there are no issues. If they don't uplist prior to news, I'm thinking we'll have time to buy more post news better than if on NASDAQ.

Good luck to us all. It's been a long ride already but we're nearly there. Thanks for all your input along the way.

Thanks...Just wasn't sure on the fully diluted share count.

AXSM MC now about $920M. With good results, I don't see why RLMD wouldn't be comparable by year's end. That would have our pps at over $20 I believe.

I've learned with some other bio-stocks that good news is often on a Monday pre-market. Bad news often on a Friday aftermarket so shareholders can collect their thoughts before acting.

The sample set I allude to is not very robust, however. So many exceptions.

I'd like to see an announcement by Wednesday of the week prior to announcing (Tuesday or Monday even preferred) so that interest and attention has time to build.

There's definitely a limit to how long they can hold the known data. Can't recall exactly that timeline but 2 weeks rings a bell.

There is a lot of literature strongly linking neuropathic pain and depression. Also, P1 has a tolerability focus and is not intended to be tried on sick (severely depressed) patients. Almost only mentioning pain (in what you've found concerning P1) perhaps is simply casting a wider net in P1 allowing for more versatility to then focus on a more narrow indication such as MDD (still related to pain) in P2 if tolerability is determined. Just some thoughts and only my opinion based on my general understanding which is hardly in depth or scientific (and if I'm even understanding what you're pointing to, Biobonic) ;)

On what topic do you stand corrected, Vic? The Nasdaq timeline in regards to the data release?

Who knows what they'll do, however, there is some logic to data first. If results are good, no RS potentially needed to uplist as even on the OTC, we'd likely get over $5 with good results.

Thanks for all the great posts here, Biobonic.

Last trial patient is complete. Anyone know when Nasdaq uplist (if so) or results are to be made public?

I believe there were 60-65 patients in the trial. Won't be long I presume.

What's our vector, Victor?

$25/share is about $1.7 Billion MC with your earlier calculations ($16/sh = 1B). Are you suggesting CC wouldn't let it go for this level or less?

Mr. Casamento was the founder of Questcor Pharmaceuticals where he was president, CEO and chairman. In 2014 Questcor was acquired by Mallinckrodt for approximately $6 Billion.

Thanks for the posts.

Where are you, VictorMasonisRight? We miss your posts.

Looks like they're full court pressing the Nasdaq uplisting. Look at the new 8k.

VicMason was saying before on this thread that uplisting alone creates a 70% return on average for smaller companies. I haven't verified that but sounds plausible logically and considering the source. Some people and tutes simply won't buy OTC stocks.

https://ih.advfn.com/stock-market/USOTC/relmada-therapeutics-inc-RLMD/stock-news/80421645/current-report-filing-8-k

I use AXSM as a decent barometer of Market Cap potential given the stage. They're at about 922M MC currently with a drug to treat the same indications: TRD/MDD. Theirs does not have as compelling a MOA like d-meth, apparently it's just an old depression drug mixed with some cough syrup. The FDA is not as intrigued by such formulations from my understanding (tweaking old drugs).

If a BO were to take place between successful P2A results and any further testing, I'm thinking we're going to be in that neighborhood (@1B) so around $16/share like you say. Of course, they may negotiate something better or worse or go it alone. I also doubt they'll go it alone. I'd be content with $16/share this year. Could be much better.

Only weeks away potentially. Good luck to us all (& the MDD patients).

We’re in the quarter of reckoning. Maybe see NASDAQ uplisting and P2a results this Q3. Been in this a couple years waiting for these results so it’s pretty exciting. What’s everyone’s PT by EOY assuming good results? I see $12-15/share.

That d-meth is more like ketamine (which is proven effective) than some other MOAs gives me confidence.

I’ve also seen a lot of sell-offs on other bio stock’s good news (even FDA approval). Serious question. What’s to keep that from happening here? I plan to hold for the bigger payday as once the results are good, there doesn’t seem to be much that can happen to keep it from progressing as word spreads. Such an incredibly huge market (over 100B from what I understand). GLTA.

One might glean that the drug is working and that the typical lack of motivation in depressed patients is being remedied. However, what about the placebo group as this is a placebo controlled trial? They were amongst those that didn't drop out as well.

Terribly sorry to hear that news, Vic. My sincere condolences.

I gathered the same from the webcast: NASDAQ may come after data. That, and data may be revealed early to mid August.

For others, webcast is linked here: http://wsw.com/webcast/ldmicro16/rlmd/

30 PT? AXSM is at 733M MC so if that's a comparable for RLMD (after hopeful very good imminent data for RLMD P2A), I see us around 20+ as well by year's end. IMO. RLMD may be valued better because it's not a combo and is a new MOA.

If RLMD is BO, do we just get our share price of the BO and we're out? That is, if it's BO at $15, for instance, is that the end of the journey for us? I've not experienced a BO and simply don't know how that works.

New VTGN versus RLMD article. I'm in long on both as I figure it's doubling my chances on a blockbuster CNS/MDD solution.

https://seekingalpha.com/article/4250010-vistgen-relmada-competitors-depression-treatment#alt2

New analyst coverage for RLMD vs VTGN

https://seekingalpha.com/article/4250010-vistgen-relmada-competitors-depression-treatment#alt2

Nice find, Mason. Do you have a link to that concerning the 300k investment? Or the person's name? The link you provided was just a VTGN overview. Thanks.

The RLMD volume today is already over 6x average and it's only mid-day. We're getting close to read out. Good luck to all holding RLMD. I've been in for over 18 months.

New interview with Singh about J&J.

https://cheddar.com/media/seeking-a-cure-vistagen-therapeutics-potential-anti-depression-drug

Watch today's Relmada Biotech Showcase presentation here: https://bit.ly/2Rawg77

4:30PM Pacific Time/7:30PM Eastern (Today 1/7/2019)

Sorry to hear that, Mason, but glad you're now out. Be well! Let's get you $15+ on the share price so you can net profit. With all the options the directors appear to automatically get (hundreds of thousands from what I can decipher on the site if I'm reading it right), maybe they don't need to invest much further. Not sure. Thanks for your insights.

I believe they need a $4 stock price for 30 of the most recent 60 days to uplist which would render this unachievable by Jan 7.

Thanks, Mason...I don't see Relmada on that presenters list.

Looking forward to see what tomorrow’s ACNP presentation will do to RLMD's exposure. Mason, your $15-$30/share prediction by July ’19 would certainly be acceptable. :)
What estimated market cap and shares outstanding are you using to predict that? How many warrants are out there to consider for dilution to add to the current @25M shares? I read that Allergan paid @$571 million upfront plus backend payments (to over 1B) to acquire Naurex’s rapastinel, (IV admin, less desired of course) a few years back. Just curious…Thanks for your posts.

Agreed, Mason. It's riding on the pending P2a results, however, as the rest would be moot if poor results, no? Would be a huge population and unmet need. Seems undervalued currently @30M MC IMO. Not sure why there isn’t more enthusiasm and volume around this stock given these circumstances.